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ABSTRACT
Objectives: Neuritin 1 gene (NRN1) is involved in neurodevelopment processes and synaptic
plasticity and its expression is regulated by brain-derived neurotrophic factor (BDNF). We aimed to
investigate the association of NRN1 with schizophrenia-spectrum disorders (SSD) and bipolar
disorders (BPD), to explore its role in age at onset and cognitive functioning, and to test the
epistasis between NRN1 and BDNF. Methods: The study was developed in a sample of 954 SSD/BPD
patients and 668 healthy subjects. Genotyping analyses included 11 SNPs in NRN1 and one
functional SNP in BDNF. Results: The frequency of the haplotype C-C (rs645649–rs582262) was
significantly increased in patients compared to controls (P¼ 0.0043), while the haplotype T-C-C-T-
C-A (rs3763180–rs10484320–rs4960155–rs9379002–rs9405890–rs1475157) was more frequent in
controls (P¼ 3.1 105). The variability at NRN1 was nominally related to changes in age at onset
and to differences in intelligence quotient, in SSD patients. Epistasis between NRN1 and BDNF was
significantly associated with the risk for SSD/BPD (P¼ 0.005). Conclusions: Results suggest that: (i)
NRN1 variability is a shared risk factor for both SSD and BPD, (ii) NRN1 may have a selective impact
on age at onset and intelligence in SSD, and (iii) the role of NRN1 seems to be not independent of
BDNF.
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Introduction
Schizophrenia and bipolar disorder are psychiatric
disorders characterised by a prevalence of 2–3%,
which increases up to 3.5% when other affective and
non-affective psychotic disorders such as schizoaffective
or schizophreniform disorders are also included (Perala
et al. 2007). A growing body of research suggests that
schizophrenia-spectrum disorders (SSD) and bipolar
disorders (BPD) share several epidemiological, clinical,
neurobiological and genetic characteristics, raising
important questions about the boundaries and distinct-
iveness of these psychiatric disorders.
On the one hand, they have a number of symptoms in
common particularly in acute episodes, with regard to the
presence of psychotic symptoms; their age at onset is
quite similar; and, although there must be neurochemical
differences, several findings emphasise the likelihood of
dopamine dysregulation in both (Murray et al. 2004).
Available evidence also supports that a generalised
deficit is present across SSD and BPD, even though
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quantitative differences may exist (Hill et al. 2013). In view
of these similarities, the integration of categorical and
dimensional approaches has been suggested of particular
interest to the complete understanding of psychotic
disorders (Peralta and Cuesta 2007).
On the other hand, an important genetic overlap
between SSD and BPD has been classically reported by
both epidemiological (Gottesman 1991; Lichtenstein
et al. 2006) and molecular studies (Owen et al. 2007).
More recently, genome-wide approaches have evidenced
a substantial shared polygenic contribution involving
thousands of common genetic variants of small effect to
the aetiology of these disorders (Lee et al. 2013).
These shared genetic risk factors, along with the
clinical and cognitive similarities, have led to the notion
that these severe mental disorders can be placed in the
same aetiopathological continuum, probably represent-
ing different phenotypic manifestations of common
underlying processes.
In the search for specific genetic factors related to
these disorders, studies face a number of challenges that
arise from the genetic and phenotypic complexity of
these disorders. To this respect, it has been recently
indicated that combining disorders with similar genetic
risk profiles improves power to detect shared risk loci
(Ruderfer et al. 2014). Similarly, genotype–phenotype-
based approaches and the use of features with strong
aetiological significance have been suggested as a useful
strategy to reduce heterogeneity and to identify specific
genetic factors associated with such traits (Rasetti and
Weinberger 2011; Swerdlow et al. 2015). Then, the
observed variability on traits such as cognitive impair-
ments and age at onset among patients may reflect
differences in the distribution of aetiological factors and
possibly also differences underlying vulnerability. To this
respect, heritability estimates indicate that genetic
factors contribute significantly to age at onset of
psychotic symptoms (Hare et al. 2010) and to general
cognitive functioning (Deary et al. 2009). Moreover,
cognitive impairments are present in 70% of the patients
with schizophrenia (Palmer et al. 1997) and twin studies
have shown that a large genetic overlap underlies the
observed comorbidity between these two phenotypes
(Toulopoulou et al. 2007, 2010). Also, the earlier forms of
these disorders usually present severe clinical and
cognitive expression, high incidence of treatment refrac-
tion and poor outcome (Rapoport et al. 2005; Joseph
et al. 2008). Accordingly, cognitive and clinical traits
associated to age at onset may provide leads for
recognising and studying biological differences across
diagnostic boundaries (Ongur et al. 2009).
Linkage data have provided positional evidence
implicating the short arm of chromosome 6 in the risk
for SSD and also in their associated cognitive deficits
(Straub et al. 1995; Schwab et al. 1995; Hallmayer et al.
2005). The most studied gene included in this chromo-
somal region is Dysbindin-1 gene (DTNBP1, 6p22.3),
which has been consistently associated with SSD and
BPD (Schwab and Wildenauer 2009) as well as with age at
onset and cognitive deficits (Wessman et al. 2009; Fatjo-
Vilas et al. 2011). Also in this region, and far less explored,
there is the Neuritin 1 gene (NRN1, 6p25.1), also called
candidate plasticity-related gene 15 (cpg15) (Nedivi et al.
1993). During early embryonic development, NRN1 is
expressed in multiple brain regions and acts as a survival
factor for neural progenitors and differentiated neurons
(Putz et al. 2005). Later in development, NRN1 promotes
growth and stabilisation of axonal and dendritic arbours
alongwith synapse formation andmaturation (Cantallops
et al. 2000; Javaherian and Cline 2005). NRN1 continues to
be expressed in the adult brain, where its expression is
correlated with activity-dependent functional synaptic
plasticity (Corriveau et al. 1999; Harwell et al. 2005; Flavell
and Greenberg 2008). Furthermore, the expression of
NRN1 is regulated by neurotrophins such as brain-derived
neurotrophic factor (BDNF, 11p13) (Naeve et al. 1997;
Karamoysoyli et al. 2008). BDNF promotes the differen-
tiation and growth of developing neurons in central and
peripheral nervous systems (Buckley et al. 2007) and its
intracellular distribution and activity-dependent secre-
tion is altered by the Met variant of a functional
polymorphism in the BDNF gene, which consists of a
valine (Val) substitution for methionine (Met) at codon 66
(Val66Met). Interestingly, BDNF gene polymorphisms
have been associated with clinical characteristics – such
as age at onset – and cognitive functioning in both SSD
and BPD (Krebs et al. 2000; Rybakowski et al. 2006).
According to all the above mentioned, NRN1 was
already defined as a candidate gene for neurodevelop-
ment disorders by Chandler et al. (2010), who reported
the effect of NRN1 polymorphic variation on general
intelligence impairments in patients with schizophrenia.
We considered the interest of investigating the implica-
tion of NRN1 in the aetiology not only of schizophrenia,
but also across the SSD and BD continuum. Moreover,
we also aimed to extend the previous study on the
relationship of NRN1 with cognitive impairments by
testing the effect of this gene on age at onset, a
characteristic that is related to cognitive performance.
Since synaptic plasticity alterations have been sug-
gested to be present both in SSD and BPD (Craddock
et al. 2006), we hypothesised that sequence variability of
the gene would be related to the risk for developing any
of these disorders. Considering the described involve-
ment of NRN1 in cognitive processes, we also hypoth-
esised that NRN1 gene could exert its effect not only by
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modulating general cognitive functioning, but also age
at onset. Finally, given that NRN1 is a BDNF-regulated
gene, we explored the statistical epistasis between NRN1
and BDNF as a proxy analysis of their involvement in
common biological pathways.
Materials and methods
Sample
The patients’ sample comprised 954 individuals of
Spanish Caucasian origin. They were drawn from con-
secutive admissions to three Child and Adolescent
Psychiatry Units and four Adult Psychiatric Units, and
were evaluated by experienced psychiatrists. All of them
met the DSM-IV-TR diagnosis criteria: 73% SSD (49%
schizophrenia, 11% schizophreniform disorder, 8% schi-
zoaffective disorder, 5% psychotic disorder NOS) and
27% bipolar disorder I or II. Exclusion criteria included:
age above 65 years, major medical illnesses that could
affect brain functions, substance-induced psychotic dis-
order, neurological conditions, history of head trauma
with loss of consciousness and having at least one
parent not from Spanish Caucasian origin. Patients were
diagnosed based on the following schedules: KSADS
(Kaufman et al. 1997) for patients up to 17 years of age,
and SCID (First et al. 1997) or CASH (Andreasen et al.
1992) for adult patients. Age at onset of the first episode
was determined by means of these clinical schedules
and/or the SOS inventory (Perkins et al. 2000).
The control sample consisted of 668 Spanish
Caucasian unrelated adult healthy individuals. They
met the same exclusion criteria as patients. They were
recruited from university students and staff, and their
acquaintances, plus independent sources in the com-
munity. They were interviewed and excluded if they
reported a history of mental illness and/or treatment
with psychotropic medication.
All participants provided written consent after being
informed about the study procedures and implications.
In the case of patients below the age of 18, written
informed consent was also obtained from their parents
or legal guardians. The study was performed in accord-
ance with the guidelines of the institutions involved and
was approved by the local ethics committee of each
participating centre. All procedures were carried out
according to the Declaration of Helsinki.
Neurocognitive assessment
The general cognitive performance was evaluated in 607
patients and in 476 healthy subjects. Intellectual quotient
(IQ) was estimated using the Block Design and Vocabulary
or Information subtests of the WAIS-III (Wechsler 1997) or
WISC-IV (Wechsler 2004), in accordance with the method
suggested by Sattler (2001). Cognitive assessment was
carried out by experienced neuropsychologists. In
patients, the cognitive evaluation was conducted when
stabilisation of symptoms and readiness for cognitive
evaluation was decided by the clinical team.
Molecular analyses
Genomic DNA was extracted from peripheral blood cells
or from buccal mucosa using standard methods: the Real
Extraction DNA Kit (Durviz S.L.U., Valencia, Spain) or the
BuccalAmp DNA Extraction Kit (Epicentre
Biotechnologies, Madison, WI, USA).
Coverage of NRN1 genomic sequence and 10 kb
upstream and downstream was achieved by including 11
tag SNPs (Table 1). The optimal set of SNPs that contained
maximum information about surrounding variants was
selected by using SYSNPs (http://www.sysnps.org/) with a
minor allele frequency (MAF)45%, using pairwise option
tagger (threshold of r2¼0.8). The SNPs included in the
study by Chandler et al. (2010) study were also con-
sidered. The SNP rs6265 (Val66Met) at BDNF gene was
also genotyped. Genotyping was performed using a
fluorescence-based allelic discrimination procedure
(Applied Biosystems Taqman 50-exonuclease assays).
Standard conditions were used. The genotyping call
rate for all SNPs was higher than 94.2% and all were in
Hardy–Weinberg equilibrium.
Statistical analyses
All data were processed using SPSS 21.0 software (SPSS
IBM, New York, USA). Haploview v4.1 (Barrett et al. 2005)
was used to estimate the Hardy–Weinberg equilibrium
and the linkage disequilibrium (LD) between NRN1 SNPs
(Supplementary Figure S1 available online). By means of
using the Solid Spine criteria three haplotype blocks
were identified (Block 1: SNP1-SNP3, Block 2: SNP4-SNP5
and Block 3: SNP6-SNP11) and a sliding window analysis
was conducted within each block.
The genetic power was calculated using Epi-info-v3.5.1
(Dean et al. 1991) by assuming an additive model, a
disease prevalence of 3% and considering theminor allele
frequencies observed in our sample. All markers had an
80% power to detect a genetic effect with an OR 1.2.
Case–control associations were analysed using the
Unphased-v3.1.4 (Dudbridge 2003), using a cut-off
threshold for rare haplotypes of 1%. A 10,000-permuta-
tions procedure was applied to all tests to limit type II
error. The odds ratios (OR) were estimated from the
absolute number of alleles/haplotypes estimated in
patients and controls (EpiInfo-v3.5.1).
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Additive models as implemented in Plink 1.07 (Purcell
et al. 2007) were used to conduct lineal regression
analyses to explore the relationship between NRN1 and
age at onset and IQ. First, the relationship between the
NRN1 and age at onset was tested in the complete
patients’ sample (including gender and diagnosis group
as covariates) and also separately in each group
(adjusted by gender). Second, the relationship between
the NRN1 and IQ was tested in the complete patient’s
sample (including age at onset, months of evolution and
diagnosis group as covariates) and also separately in
SSD, BPD (adjusted for age at onset and months of
evolution) and controls. PLINK’s max(T) permutation
procedure with 10,000 iterations was performed.
The effect of NRN1 and BDNF interaction was tested
on: (i) the risk for developing SSD or BPD, (ii) age at onset
(adjusted for sex and diagnosis) and IQ (adjusted for age
at onset and months of evolution), in patients. Epistasis
was explored using the model-based multifactor dimen-
sionality reduction (MB-MDR) approach by applying
‘mbmdr’ R-package (Calle et al. 2010). This method
merges multi-locus genotypes in order to overcome the
dimensionality problem and to increase the power to
detect gene interactions associated with disease or
phenotype. It also allows adjusting for confounding
effects and correcting for multiple testing by 1000
permutations approach. In all analyses, the significance
cut-off was established at P value of 0.05.
Results
Sample characteristics
Table 2 shows the main sociodemographic and clinical
data of the sample. Variables that showed differences
between groups were used as covariates when appro-
priate (see Statistical analyses section).
Association analysis of NRN1 and schizophrenia-
spectrum and bipolar disorders
There were no differences between sampling groups as
regards the genotypic distribution of each polymorph-
ism (data not shown), and genotype frequencies showed
no gender differences within groups (patients and
controls; data not shown).
SNP1 (G allele), SNP4 (C allele) and SNP5 (C allele)
were significantly more frequent among patients com-
pared to controls (2¼4.81 P¼ 0.028, 2¼5.05 P¼ 0.024
and 2¼8.04 P¼ 0.004, respectively). After multiple
correction adjustment only the association of SNP5
remained significant (OR(95%CI)¼ 1.27(1.07–1.49),
empirical P value¼ 0.044)).
Haplotypes associated with SSD and BPD are given in
Table 3. The frequency of the haplotype G-C (Block 1:
SNP1-SNP2) and haplotype C-C (Block 2: SNP4-SNP5) was
significantly increased in patients than in controls. The
result in Block 2 remained significant after permutation
procedure; then, this haplotype was considered a risk
haplotype for SSD and BPD. On the contrary, the
haplotype T-C-C-T-C-A (Block 3: SNP6-SNP11) had higher
frequencies in controls. Results in Block 3 also remained
significant after multiple testing and could be interpreted
as reflecting a protective effect of this haplotype. Note
that other haplotypes included in the haplotype in Block
3 were also detected (Supplementary Table S1 available
online). These results remained essentially unchanged
when only SSD patients and controls were included.
NRN1 and age at onset of the disorders
Patients carrying two copies of the T allele at SNP2
(15.33%) presented a lower age at onset than those not
carrying this allele (b¼ –0.772 P¼ 0.029). Patients homo-
zygous for the C allele of SNP10 (7.80%) also showed later
age at onset than those not carrying this allele (b¼ 0.918
Table 1. SNPs genotyped in Neuritin 1 gene (NRN1, chromosome 6p25.1, from 598233 to 6007633 bp).
SNP Position Region
Distance from
SNP1
Distance from
previous SNP Allelesa MAFb
SNP1 rs2208870 5992490 Intergenic A/G 0.333
SNP2 rs12333117 5994992 Downstream 2502 2502 C/T 0.402
SNP3 rs582186 6001381 Intronic 8891 6389 A/G 0.393
SNP4 rs645649 6004959 Intronic 12469 3578 C/G 0.356
SNP5 rs582262 6007991 Upstream 15501 3032 G/C 0.273
SNP6 rs3763180 6009848 Upstream 17358 1857 G/T 0.437
SNP7 rs10484320 6010437 Upstream 17947 589 C/T 0.236
SNP8 rs4960155 6010539 Upstream 18049 102 T/C 0.492
SNP9 rs9379002 6012391 Intergenic 19901 1852 T/G 0.27
SNP10 rs9405890 6012721 Intergenic 20231 330 T/C 0.309
SNP11 rs1475157 6017169 Intergenic 24679 4448 A/G 0.176
The table includes the dbSNP number, the genomic and gene position and the alleles of the 11 SNPs genotyped along the gene (UCSC Genome Browser on
Human Mar. 2006 Assembly (hg18), http://genome.ucsc.edu/cgi-bin/hgTracks).
aThe less frequent allele (minor allele) is placed second.
bMAF refers to Minor Allele Frequency observed in the 1000 Genomes project (Abecasis et al. 2012).
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P¼ 0.016). The haplotype C-A (SNP10-11) was associated
with age at onset: (b¼ 0.956 P¼ 0.015) and also several
haplotypes within Block 3 (all including the C-A haplo-
type) (Supplementary Table S2 available online).
When the same analysis was conducted only includ-
ing SSD patients, the results for SNP10 and haplotype
SNP10-11 remained significant while SNP2 did not
(Supplementary Table S3 available online). In an additive
way, carrying two copies of the haplotype C-A was
associated with later SSD age at onset (Figure 1A).
However, these results were not significant after
permutation procedure. No association was detected
within BPD patients’ group.
NRN1 and cognitive functioning
In SSD patients, the same haplotypes within Block 3
contributed to IQ scores (Supplementary Table S4
available online). A linear trend was detected between
the number of copies of these haplotypes and higher IQ
scores (Figure 1B), meaning that subjects carrying these
haplotypes showed better general cognitive
Table 3. NRN1 most significant haplotypes associated to the risk for schizophrenia-spectrum and
bipolar disorders. Frequency estimates in patients and controls, significance levels and OR of the
case-control comparison are given.
SNP1
SNP2
rs2208870
rs12333117
G
I
C
SNP3 rs582186
SNP4
SNP5
rs645649
rs582262
C
I
C
SNP6
SNP7
SNP8
SNP9
SNP10
SNP11
rs3763180
rs1048432
rs4960155
rs9379002
rs9405890
rs1475157
T
I
C
I
C
I
T
I
C
I
A
Ca- Freqa 34.3 25.9 0.1
Co- Freqb 30.7 21.4 1.5
2
OR (CI 95%)c
4.26
1.18 (1.01–1.37)
7.99
1.28 (1.08–1.51)
17.45
0.09 (0.02–0.37)
Global P value 0.11 0.038 0.001
Individual haplotype P value 0.037y 0.0043* 0.000031**
aCa- Freq refers to each haplotype frequency within cases.
bCo- Freq refers to each haplotype frequency within controls.
cChi-squared tests and OR were estimated from the absolute number of observed haplotypes in cases and controls.
yNot significant after performing 10,000 permutations, adjusted P value from permutation test P¼ 0.1748.
*Significant adjusted level based on 10,000 permutations, adjusted P value from permutation test P¼ 0.0219.
**Significant adjusted level based on 10,000 permutations, adjusted P value from permutation test P¼ 0.002.
Table 2. Sample description and statistical comparisons between patients and controls.
All Patients (n¼954) SSD (n¼697) BPD (n¼257) Controls (n¼668)
Male (%) 65.6% 71.2% 50.6%** 46.7%*
Age at interview 32.33 (13.10) 31.79 (12.83)** 33.9 (13.71)** 27.05 (9.99)*
Years of education 10.13 (4.06) 9.58 (3.82) 11.98 (4.29)** 13.87(2.87)*
Age at onset 21.54 (6.47)a,b 20.72 (5.33)a 23.88(8.53)a,** –
Months of evolution 146.24 (137.6) 140.35 (140.07) 162.93 (129.25) –
Current IQ 89.80 (15.26)c 89.02 (15.37)c 92.86 (14.48)c,** 99.48 (13.64)c,*
Proportion (%) or mean scores (standard deviation) are given. SSD, schizophrenia-spectrum disorders; BPD, bipolar disorders.
aInformation about age at onset was available for the 73.5% of patients (74.3% SSD and 71.2% BPD).
b35.29% were classified as early-onset (first psychotic episode occurred before 18 years of age).
cInformation about IQ was available for 63.6% of patients (69.4% SSD and 47.8% BPD) and 71.25% of healthy subjects.
*Controls differed significantly from patients (P50.001).
**BPD patients differed significantly from SSD patients (P50.03).
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performance than non-carrier subjects. However, after
permutation analyses these results did not remain
significant. No significant association with IQ was
detected between these polymorphisms either in the
whole patients’ sample, in BPD or in healthy subjects.
Epistasis between NRN1 and BDNF
Two order gene–gene interaction models were devel-
oped and revealed that the combination of the BDNF
Val/Val genotype with different NRN1 variants (SNP1 (GG:
b¼ 0.654 P¼ 0.001), SNP3 (AA: b¼ 0.514 P¼ 0.003) and
Figure 1. Relationship between NRN1 and age at onset and IQ in SSD patients. Linear regression graphs showing the relationship
between SSD patients’ NRN1 haplotypes and: (A) age at onset, (B) IQ. For illustration purposes, the haplotype dump option was used
to estimate individual haplotype phases. Considering only those haplotypes estimated with a probability95%, each subject was
defined according to its haplotype dose. (A) The haplotype C-A (SNP10-11) was selected to represent graphically the described
association between NRN1 and age at onset (b¼ 0.89 P¼0.019). SSD patients were classified as: 47.01% non-carriers (0), 45.41% one-
copy carriers (1) and 7.58% two-copy carriers (2). (B) The haplotype C-T-G-C-A (SNP7-11) was selected to represent graphically the
detected association between NRN1 variability and IQ within SSD patients (b¼ 4.02 P¼0.022). SSD patients were classified as: 82.2%
non-carriers (0), 16.9% one-copy carriers (1) and 0.9% two-copy carriers (2).
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SNP9 (TG: b¼ 0.457 P¼ 0.0004)) was related to an
increased risk for developing both SSD and BPD. In
contrast, BDNF Met/Met was associated with a lower risk
in combination with NRN1 SNP2 (TT: b¼ –2.185
P¼ 0.0052). After permutation analysis, the interaction
BDNFxNRN1SNP9 remained significant (P¼ 0.005). No
significant epistatic effect was detected on age at
onset and IQ after permutation.
Discussion
This case–control based approach adds to the only one
previous Neuritin 1 gene association study developed by
Chandler et al. (2010) in a sample of 336 patients with
schizophrenia and 172 controls. Unlike Chandler and
collaborators, in our sample of 954 patients and 668
healthy subjects we report that NRN1 sequence variabil-
ity accounts for a modest proportion of the risk for these
disorders. On the one hand, we have identified a two
SNP haplotype (SNP4-SNP5: C-C) that is associated with
the risk for these disorders. As expected, due to the
polygenic architecture of the studied disorders, the
effect of this haplotype is small although significant
(OR¼ 1.28). On the other hand, we have observed
haplotypes in the 5 upstream region that have a
protective effect. Although significance for these asso-
ciations persisted after permutation procedure, the low
frequency of the protective haplotypes in the population
has to be considered when evaluating the attributable
risk associated to these genetic variants.
The present study also provides new evidence of
interest as regards understanding the heterogeneity in
age at onset and cognitive performance of SSD and BPD.
Our results suggest that NRN1 variability has a role in
SSD age at onset, pointing towards a specific effect on
modifying neurodevelopment processes related to the
time of emergence of these disorders. Although these
results should be interpreted cautiously because they
are only significant at an uncorrected level, it is
interesting to note that the C allele of SNP10, which is
included in the above described protective haplotype, is
associated with a later age at onset of SDD. Then, taking
into account that the 51% of SSD patients are carriers of
this allele (358 C carriers vs 339 TT), together with the
particularly poor prognosis associated to schizophrenia
in childhood and adolescence in contrast to the adult
manifestation (Clemmensen et al. 2012), this modulatory
effect is of non-dismissible potential clinical interest.
Our study also shows the association between this
gene and intelligence in SSD. This selective impact of
NRN1 on intelligence may suggest its involvement in
processes underlying cognitive functioning, which are
described to be more quantitatively impaired in SSD
(Hill et al. 2013). Again, although results did not reach
significance after permutation, it is of interest that the
haplotypes identified in the present study contain the
same haplotype that Chandler et al. (2010) described to
be associated with better fluid intelligence in schizo-
phrenia patients and not in healthy subjects (SNP10-
SNP11: C-A).
In all, our results suggest in a convergent manner that
allelic variants in Block 3 of NRN1 could represent a
protective factor, not only due to their association to a
reduction of the risk for SSD and BPD, but also because
within SSD patients, these variants are related to a later
of age at onset and a better cognitive performance. This
lends support to the notion that specific genetic
variability could play a role in defining illness subgroups
and points towards the interest of understanding the
pathways from genotype to clinical phenotype, which
will be crucial for new classification systems and to for
the development of novel therapeutic strategies.
In further interpreting these results, it is necessary to
consider the results obtained by whole genome
approaches. To our knowledge, NRN1 has not appeared
as a significant locus in the published GWAS for
schizophrenia and bipolar disorders. However, these
negative results could be influenced, for example, by the
small effect attributable to common variants or by the
heterogeneity of the samples. It should also be con-
sidered that NRN1 could be exerting its effect by means
of modifying more specific traits associated with psych-
otic disorders. In this regard, a genome-wide scan for
intelligence conducted in a general population sample
revealed suggestive linkage for IQ on 6p25.3–21.31 and
already highlighted NRN1 as a positional candidate gene
(Posthuma et al. 2005). Moreover, a subtype of schizo-
phrenia characterised by pervasive cognitive deficit was
also linked to 6p25–p22 region (Hallmayer et al. 2005).
More recently, a GWAS has established that common
variants (SNPs) may account for 40–50% of intelligence
variance (Davies et al. 2011) and a GWAS-based pathway
analysis has reported that general fluid intelligence
appears to be characterised by genes affecting quantity
and quality of neurons and therefore neuronal efficiency
(Christoforou et al. 2014). Among the genes included in
the top pathways identified in this study, there was the
BDNF, a regulator of NRN1 expression. According to all
these data and given the described gradual increase in
heritability of IQ from childhood to late adolescence
(Deary et al. 2009; Bouchard 2013) and the reported early
occurrence of intellectual impairment even years before
the onset of the psychotic symptoms (Cannon et al.
2002), it is plausible that those genes that influence
brain development, as NRN1, may be modulating illness
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traits, as IQ and age at onset, and ultimately influencing
the risk for these disorders.
Although the connection between the NRN1 sequence
variability and the risk for SSD and BPD is still unclear, the
consideration of the putative effects of the analysed
polymorphic sites on gene expression regulatory mech-
anisms represents a valuable resource to provide add-
itional meaning and importance to our association data.
Recent data has revealed the importance of intronic and
intergenic variants as regulatory elements of gene
expression (Dunham et al. 2012). The impact of non-
coding variants of the NRN1 SNPs can be examined using
HaploReg (Ward and Kellis 2012), which is a tool that uses
LD information from the 1000 Genomes Project to
provide data on the predicted chromatin state of the
queried SNPs, their sequence conservation mammals,
and their effect on regulatorymotifs. As an example, SNP2
(rs12333117), associated with age at onset in the present
study, is located in a downstream region, in a DNAse
region (T-47D) and it is predicted to alter several motifs
that overlap the recognition sequences of transcription
factors such as AP-1/Jun, suggesting possible factor–
factor interactions. There is also evidence that this SNP
could modify the promoter histone mark H1, which plays
an active role in the formation of epigenetic silencing
marks (Yang et al. 2013). Another example refers to the
SNP4 (rs645649), included in the identified risk haplotype
and that is located in an intronic region where two
proteins bound: SUZ12 (involved in methylation pro-
cesses leading to transcriptional repression of the
affected target genes) and ZNF263 (implicated in basic
cellular processes as a transcriptional repressor).
Furthermore, several resources provide information
about the correlation between genotype and tissue-
specific gene expression levels, which may help in the
interpretation of molecular genetics association studies
(GTEx Project, www.gtexportal.org (Lonsdale et al. 2013);
BrainCloud, http://braincloud.jhmi.edu/ (Colantuoni et al.
2011)). In this regard, variations in NRN1 expression have
been associated with SNPs along the gene. Therefore,
although functional studies are needed, the association
of NRN1 sequence variants with SSD and BPD phenotypes
could be linked to the final availability or functionality of
the protein which, in turn, could dysregulate NRN1 role
on neurite outgrowth and arborisation and/or on neur-
onal processes associated with plasticity.
Finally, based on the analyses of epistasis between
NRN1 and BDNF, our data suggest that the interaction
between the Val/Val genotype (BDNF) and the TG
genotype (NRN1, SNP9: rs9379002) could modulate the
risk for SSD and BPD. Despite the fact that evidence of a
statistical interaction as we report here does not
necessarily map directly onto biological interaction, it
is of note that it is based on a previously described
effects of BDNF on NRN1 regulation (Naeve et al. 1997).
Then, it could be hypothesised that the reported
functional effects of the BDNF Val66Met polymorphism
could impact on NRN1 availability or function, explaining
therefore the gene–gene interaction on the risk for
developing SSD and BPD and contributing to under-
stand the controversial results associated to single gene
analyses. To this respect, some studies have implicated
the BDNF Val allele in these disorders and, as the Val
allele is associated with increased synaptic plasticity and
growth (Egan et al. 2003), it has been suggested that this
allele could promote increased synaptic connections
between certain brain regions that underpin common
symptoms. However, recent meta-analyses have failed to
confirm the direct association of Val66Met polymorph-
ism with the risk for schizophrenia (Zhao et al. 2015) or
bipolar disorder (Gonzalez-Castro et al. 2014). On the
other hand, taking into account that BDNF exerts a direct
impact on neuronal growth and plasticity in the limbic
system (Conner et al. 1997; Rattiner et al. 2004), it should
be contemplated that G allele carriers of rs9379002
(SNP9, NRN1) show higher NRN1 expression than TT
homozygotes in the hypothalamus (GTEx Project). Then,
we could speculate that higher expression of both BDNF
and NRN1 could be underlying the detected epistatic risk
effect. To this respect, it is remarkable that a case-report
study suggested the relationship between a duplication
of NRN1 gene (i.e. increased gene dosage) and the white
matter and neurocognitive abnormalities observed in
one patient (Linhares et al. 2015). Accordingly, we would
have expected to detect the association not only with
the heterozygous TG genotype but also with the GG.
This lack of significant interaction could be explained by
the low frequency of GG genotype (7%) and the
corresponding low frequency of the combination of
Val/Val x GG (BDNFxNRN1SNP9). Therefore, although
further studies are needed, these results are in line
with recent trends in the field of molecular genetics,
which consider the importance of testing gene networks
rather than isolated gene effects for better understand-
ing the gene–phenotype relationship in complex dis-
orders (Gilman et al. 2012). Nonetheless, the fact that the
SNP9 is included in the protective haplotype while it is
detected to exert a risk effect when interacts with Val/Val
genotype could suggest that the effect of this SNP may
differ depending on the genetic background in which
the alleles are present (Moore 2003). Moreover, beyond
gene–gene interactions, the effect of environmental
factors should also be studied. In this regard, the fact
that NRN1 is classified as an immediate early gene
(Loebrich and Nedivi 2009), meaning that it can be
rapidly induced by extracellular stimuli and act as a
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transcription factor on downstream targets, highlights
the interest of analysing the combined effect of NRN1
and BDNF in gene-environment studies.
Some limitations of this study must be acknowledged.
First, the controls’ age range is partially overlapped with
the age range of incidence of SSD and BPD. However, due
to the fact that personal psychiatric history and treatment
was discarded, the percentage of false negatives would
be very low and should not interfere with the obtained
results. Second, the polygenic nature of mental disorders
and theminor effect of the common genetic variants limit
the power of our sample size, especially in the case of the
analyses split by diagnosis. In line with this, although the
use of features with strong aetiological significance has
been suggested as a useful strategy to increase the power
to detect genetic effects, the power of the analyses
targeting age at onset and neurocognition is reduced due
to the non-availability of data in all subjects. This
statistical power reduction could be related with the
loss of significant effects after permutation procedures.
Third, the antipsychotic treatment was not specified and,
therefore, cognitive analyses, although covaried by age at
onset and months of evolution, were not adjusted by
treatment type or duration. Fourth, in spite of the interest
of the selected polymorphism at BDNF due to its
functional effects, future studies should include other
genetic variants along this gene. Lastly, although the
permutation procedures have been applied, if multiple
testing is addressed for the overall analyses not all the
findings would remain significant. Then, although results
cannot be dismissed completely, since they come from a
directed hypothesis and they are partially in line with a
previous study (Chandler et al. 2010), their interpretation
should be conducted with caution and replication studies
are needed.
Overall, our results contribute, from a biological
approach, to the understanding of the genetic mechan-
isms involved in SSD and BPD and also of the relation-
ship between genetic variability and the clinical
heterogeneity of these disorders. Then, our findings
suggest the role of Neuritin 1 gene as a mixed
susceptibility/modifier gene (Fanous and Kendler 2008),
which increases the susceptibility to these disorders and
modifies certain presentations. However, new studies
should be developed to further acknowledge the
involvement of NRN1 and its interaction with other
genes in the aetiology of mental disorders.
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